In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk

Over the last two days, Novo Nordisk A/S (NYSE:NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.Novo Nordisk 2026 GuidanceNovo Nordisk expects sales growth for 2026, which excludes revenue of $4.2 billion from the reversal of 340B provisions, is expected to be -5% to -13% at CER.The company said that the sales outlook is impacted by lower realized prices, including impacts related to the "Most Favoured Nations" agreement in the U.S. and the patent expiry of the sem ...